Kelley Julian

1 month ago | nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more

AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.

Mar 3, 2025 | nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more

TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.